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Abstract 
 
Background: This prospective study  compare concurrent weekly and three weekly cisplatin based concurrent 
chemoradiotherapy in locally advanced cervical cancer.Methods: The study was conducted in 40 patients with 
locally advanced carcinoma cervix  randomised into 2 arms. Arm A patients received external beam Radiotherapy 
(EBRT) to pelvis with concurrent weekly cisplatin at dose of 40 mg/m2 and arm B patients received EBRT to pelvis 
with concurrent three weekly cisplatin at dose of 75 mg/m2 followed by high dose rate intracavitary brachytherapy 
(HDR ICBT). Acute  gastrointestinal (GI) toxicities being common and worrisome complication and response rates 
were analysed.Results: The patient and disease characteristics were comparable in both arms. There was no 
significant difference in both arms in terms of lower GI toxicity i.e weekly vs three weekly(75% Vs 80%; P = 0.208) 
. Compliance to chemoradiation was better in three weekly vs weekly (85% vs 70%) cisplatin arms but not 
statistically significant (p<0.05) After a median follow up of 18 months, tumor control rates in both arms were 
comparable (85% Vs 90%; P = 0.128).Conclusion: The present study observations suggest that concurrent weekly 
or three weekly cisplatin based chemo-radiation therapy is equally effective in treatment of cervical cancer in terms 
of local tumor control rate,lower GI toxicity and patients compliance to proposed chemoradiotherapy treatment. 
However randomised trials with larger sample sizes and longer duration of follow up are required. 
Keywords: cisplatin, concurrent chemoradiation, carcinoma cervix.  
Introduction 
 
 
Carcinoma of uterine cervix is the most common 
gynaecological malignancy worldwide and in 
India.[1,2]  Majority of patients present as locally 
advanced stage in our country unlike the western 
affluent society due to lack of universal screening 
and awareness among women.  
____________________ 
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Concurrent cisplatin‑based chemoradiotherapy (CRT) 
is the treatment of choice in locally advanced cervical 
cancer based on five randomised trials. [3-8] Most 
widely accepted CRT is weekly cisplatin at dose of 
40-50 mg/m2. Several other trials used 3 weekly 
cisplatin 75–100 mg/m2 because of the ease of 
administration and improved patients’ compliance 
which shows almost similar toxicity profile and 
clinical outcome compared to concurrent weekly 
cisplatin. The present study was conducted to 
compare and evaluate the compliance, efficacy and 
toxicity profile especially the gastrointestinal and 
genitourinary complication between two different 
dosing schedules of concurrent cisplatin, i.e., once in 
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three weekly cisplatin (75 mg/m2) with weekly 
cisplatin (40 mg/m2) in treatment of locally advanced 
carcinoma cervix. 
 
Patients and Methods 
This prospective randomised study was conducted on 
histopathologically proven locally advanced 
carcinoma cervix patients from March 2015 to 
August 2017, A total of sixty patients were screened 
out of which Forty patients were randomised by 
computer‑generated random number tables; twenty 
patients to each arm. Arm A (external beam 
radiotherapy (EBRT) + weekly cisplatin 40 mg/m2 
followed by high‑dose rate intracavitory 
brachytherapy (HDR ICBT) and arm B (EBRT + 3 
weekly cisplatin 75 mg/m2 followed by HDR ICBT). 
The study was started after getting approval from the 
institutional ethics committee. Written 
informed consent was taken from the patients before 
the start of treatment.The International Federation of 
Gynaecology and Obstetrics staging system was used 
to stage the patients. The study was conducted on 
patients meeting eligibility criteria: age ≤65 years, the 
Eastern Cooperative Oncology Group performance 
status 0–2, haematologic parameters ([haemoglobin 
(Hb) ≥10 gms/dl) , total white blood cell count 
≥4000/mm3 and platelets ≥100,000/mm3]) and renal 
function (calculated creatinine clearance ≥60 
mL/min). 
Radiotherapy was delivered by combination of EBRT 
and HDR ICBT. All patients were treated with 15 
MV photons, EBRT. Patients were treated by two 
fields (AP/PA)/four‑field technique if the 
anteroposterior‑posteroanterior (AP‑PA) separation 
was >20 cm in the supine position. All patients were 
planned in the supine position without any bladder 
protocol. The superior border for the AP‑PA field 
was kept at L4 to L5 interspace and inferior border at 
the inferior border of obturator foramen or lower 
depending on disease extension to the vagina to cover 
tumour with a margin of 2 cm. The lateral border was 
kept 2 cm from the lateral pelvic brim. For lateral 
fields, the superior and inferior borders were same as 
AP‑PA field. The anterior border was kept just in 
front of the pubic symphysis, and the posterior border 
was set to cover the entire sacral hollow. Dose was 
delivered to the centre of field with isocentric 
technique.Radiation was delivered by conventional 
fractionation to a total dose of 46–50 Gy at the rate of 
2 Gy per fraction, single fraction per day and five 
fractions per week in 23–25 fractions over a period of 
5–6 weeks. 
High dose rate intracavitary brachytherapy (HDR 
ICBT) was performed by using  with Ir192 isotope 
with an interval of one week between two fractions. 
Patient was assessed for ICBT fitness after 
completion of 15-20 fractions of EBRT. ICBTwas 
planned when the os was able to sound. Modified 
Fletcher suit applicator – Central intrauterine tandem 
and paired ovoids or a tandem and ring of different 
sizes were used according to individual patient’s 
anatomy. The prescribed dose was 600-800 cGy per 
fraction in 3-4 fractions to point A.  
Chemotherapy cisplatin was given concurrently with 
EBRT once weekly (40 mg/m2) for a total of five 
cycles in arm A and once in 3 weeks (75 mg/m2) for 
a total of two cycles in arm B during the course of 
EBRT. Pre‑chemotherapy hydration was 
administered 500 ml of 0.9% saline (NS) over 1 h 
followed by prophylactic antiemetic medication with 
injection dexamethasone 16 mg intravenous (IV), 
injection palonosetron 0.25 mg IV and injection 
ranitidine 50 mg in 100 ml of 0.9% NS over half 
hour. Cisplatin 40 mg/m2 was given in 500 mL of 
0.9% NS over 2 h in arm A patients. The total dose of 
cisplatin in arm B patients who received cisplatin 75 
mg/m2 was calculated and given in 500 ml 0.9% NS 
over 2 h. It was followed by RT within 1 h after 
completion of the infusion. Post‑chemotherapy (CT) 
patients received 2 ampoules (300 mg) potassium 
chloride in 500 ml of 0.9% NS over 1hr followed by 
2 ampoules of 50% w/v magnesium sulphate in 500 
mL of 5% dextrose over 1 h. Post‑chemohydration 
with 500 mL of 0.9% NS over 1 h was given. On 
fourth day post chemotherapy laboratory 
investigations such as serum electrolytes such as 
sodium, potassium, calcium and magnesium  and 
serum creatinine were sent and hemogram sent one 
week after chemotherapy. 
During their entire treatment course, all patients were 
examined weekly or earlier whether they had 
developed acute gastrointestinal and genitourinary 
toxicities were assessed as per the Common 
Terminology Criteria for Adverse Events (CTCAE) 
Version 4 formulated by the NCI. [13] Antiemetics 
were given on day of chemotherapy and for 2 days 
after CT. Any delay causing treatment interruption 
was noted and appropriate gap corrections were done. 
Response assessment was done as per Response 
Evaluation Criteria In Solid Tumors (RECIST) 
criteria.[14] All responses were measured clinically. 
Responses to therapy were classified as complete, 
partial, stable or progressive. 
Follow up of all patients was asked for the first time, 
6 weeks after completion of treatment. Patients were 
planned to follow up every one month for 1st three 
months, every three monthly for 9 months then for 
every 4 months for two years.  Follow-up procedures 
include general, systemic and pelvic examination, 
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palpation of inguinal and supraclavicular nodes. 
Imaging studies, such as radiograph, computer 
tomography, ultrasonography, and bone scan were 
done when required. 
Statistical Analysis 
All informations collected in the approved proforma 
was recorded in a master chart in MS EXCEL 2007 . 
Data analysis was done with the help of computer 
using SPSS software version 20 (IBM SPSS 
Statistics, Somers NY, USA). Using this software, 
range, frequencies, percentages, means, standard 
deviations, chi square and 'p' values were calculated. 
All the descriptive statistical values were presented in 
the form of mean ± standard deviation. Student 
independent ‘t’ test was used to compare the means 
of different continuous variables. Pearson’s chi 
square test was performed to assess the association 
among different categorical variables. A 'p' value less 
than 0.05 is taken to denote statistically significant 
relationship. 
Results 
Patients with histopathologically diagnosed 
carcinoma of cervix during the study period were (n 
=60) screened for inclusion into the study. Of these n 
=20 were excluded from the study for several reasons 
such as patients with early cervical cancer, metastatic 
disease at presentation, post operative cases fit for 
adjuvant therapy, dual malignancies and recurrent 
cases. After exclusion n = 40 patients were in locally 
advanced stages who are eligible for concurrent CRT. 
All these  patients were recruited into study and 
patients were divided into two arms with 20 patients 
each. Arm A patients received RT along with 
concurrent weekly cisplatin and arm B patients 
received RT along with concurrent three weekly 
cisplatin followed by HDR-ICBT (Figure 1). 
 All the patient and disease characteristics like age, 
stage, size of tumor, uni or bilateral parametrial 
involvement were comparable in both arms. 
Patients in the arm A received a mean dose of 50.5 
mg per cycle, whereas patients in the arm B received 
a mean dose of 105.75 mg per cycle. The total 
cumulative dose in both the cycles was statistically 
similar with a mean of 230 mg in arm A versus 194 
mg in arm B (P = 0.9) [Table 1].All patients were 
evaluated for different toxicities according to NCI 
CTCAE version 4.0 There were no treatment related 
deaths. No dose limiting toxicities were recorded. 
Patterns of acute toxicities – haematological toxicity ( 
anemia, neutropenia, leukopenia), upper 
gastrointestinal toxicity ( nausea, vomiting), lower 
gastrointestinal toxicity( diarrhoea) and 
nephrotoxicity and electrolyte imbalances were 
evaluated between 2 arms and represented in [Table 
2]. All the patients in the study were assessed for 
treatment response 6 weeks after the completion of 
treatment using RECIST criteria. Responses were 
assessed clinically. 17(85%) patients of Arm A, 19 
(95%) patients of Arm B had complete response and 
3 patients of Arm A and 1 of Arm B had partial 
response (P =.195) after 6 weeks of completion of 
treatment (Table 3)  
After a median follow up of 12 months in arm A, 19 
patients of arm A had complete response and 1 
patient had progressive disease. After a median 
follow up of 11.5 months in arm B, 1 patient in arm 
B lost to follow up, 4 patients had progressive disease 
manifested as distant metastasis. Sites of progression 
are bone metastasis in 2 patients, 2 with 
supraclavicular lymph node recurrence.   
The results of the present study is compared with 
another similar study in Korea by Ryu etal [9]] is 
shown in [Table 4]. 
 
Table 1: Details of chemotherapy in both arms 
Variable Arm A Arm B P-value 
Dose per cycle (mg) 50.5±5.1 105.75±10.9 0.004 
Total cumulative dose (mg) 230±34.8 194±38.1 0.9 
 
Table 2: Pattern of acute toxicities of cisplatin in two arms 
Variable Arm Grade 1 Grade 2 Grade 3 Grade 4 P- value 
Anemia Arm A 12 (60) 4 (20) 1(5) 0 0.659 
Arm B 12 (60) 6 (30) 0 0 
TLC Arm A 0 5 (25) 0 0 0.197 
Arm B 3 (15) 4 (20) 0 0 
ANC Arm A 3 (15) 2 (10) 0 0 0.195 
Arm B 0 2 (10) 0 0 
Nausea Arm A 16 (80) 4 (20) 0 0 0.344 
  
 
International Journal of Health and Clinical Research, 2019;2(9):1-8                     e-ISSN: 2590-3241, p-ISSN: 2590-325X                         
                                                             
____________________________________________________________________________________________________________________________________________  
____________________________________________________________________________________________________________________________ 
Gopalkesari & Das            International Journal of Health and Clinical Research, 2019; 2(9):1-8 
www.ijhcr.com                              
        4 
 
Arm B 14 (70) 4 (20) 2 (10) 0 
Vomiting Arm A 8 (40) 5 (25) 0 0 0.208 
Arm B 6 (30) 10 (50) 0 0 
Diarrhea Arm A 11 (55) 3 (!5) 1 (5) 0 0.643 
Arm B 14 (70) 2 (10) 0 0 
Nephrotoxicity Arm A 2 (10) 0 0 0 0.212 
Arm B 5 (25) 0 0 0 
Hyponatremia Arm A 2 (10) 0 0 0 0.114 
Arm B 6 (30) 0 0 0 
Hypokalemia Arm A 2 (10) 0 0 0 0.513 
Arm B 1 (5) 1 (5) 0 0 
Weight loss Arm A 6 (30) 2 (10) 0 0 0.633 
Arm B 8 (40) 3 (15) 0 0 
 
TLC = Total leukocyte count; ANC = Absolute neutrophil count 
Table 3: Response to treatment in both arms 
Variable No of pts in arm A No of pts in arm B P-value 
Complete response 17 (85%) 19 (95%) 0.128 
Partial response 3 (15%) 1 (5%) 
Stable disease 0 0 
Progressive disease 0 0 
 
Table  4: Comparison of patient characteristics and toxicities of present study with Korean study 
Variable RYU [9] Present study 
Publication 2011 - 
Place of study Korea Tirupati, India 
Type of study Prospective Prospective 
No. Studied 104 40 
Radiotherapy 
schedule 
EBRT – 50 Gy in 1.8-2 Gy per fraction.  
(137 Cs ) LDR ICBT – 30-40 Gy in 1-2 
fractions. 
EBRT: 46-50 Gy in 2 Gy per fraction.  
HDR ICBT 24 Gy in 3-4 fractions with a gap of 
1 week between fractions. 
Chemotherapy 
schedule 
(cisplatin) 
Arm A: weekly (40mg/m2) for 6 cycles 
Arm B: triweekly (75mg/m2) for 3 cycles 
Arm A: weekly 40mg/m2 for 5 cycles. 
Arm B: three weekly 75 mg/m2 for 2 cycles. 
Mean Age (yrs) ± 
SD 
54.4 ±1.3 51.9 ±1.3 45.45 ± 8.6 51.75 ± 5.6 
Patients  in each 
arm 
51 53 20 20 
Histology SCC- 46 (90.2) 
Adeno- 5 (9.8) 
47 (88.7) 
6 (11.3) 
20 (100) 
0 
20 (100) 
0 
FIGO stage IIB - 28 (54.9)  
 III -19 (37.3)  
IVA - 4 (7.8)  
34 (64.2) 
19 (30.2) 
3 (5.7) 
12 (60) 
8 (40) 
0 
8 (40) 
12 (60) 
0 
Compliance to 
chemotherapy 
44 (86%) 49 (92.5%) 14 (70%) 17 (85%) 
Toxicities NCI CTCAE   NCI CTCAE   
Anemia ND ND Grade 1-2: 16 (80%) 
Grade 3-4: 1 (5%) 
Grade 1-2 : 
18 (90%) 
Leucopenia ND ND Grade 1-2 : 
5 (25%) 
Grade 1-2 : 
7 (35%) 
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Neutropenia Grade 1-2 20 (39%)  
Grade 3-4 20 (39%) 
Grade 1-2 23(43%) 
Grade 3-4  
12 (23%)* 
Grade 1-2 : 
5 (25%) 
Grade 1-2: 
2 (10%) 
Nausea Grade 1-2: 43 (84%) 
Grade 3-4: 2 (4%) 
Grade 1-2: 46 
(87%) Grade 3-4: 2 
(4%) 
Grade 1-2 : 
20 (100%) 
Grade 1-2: 18 (90%) 
Grade 3-4: 2 (10%) 
Vomiting Grade 1-2 
12 (24%) 
Grade 1-2  
11 (21%) 
Grade 1-2 
13 (65%) 
Grade 1-2 
16 (80%) 
Nephrotoxicity Grade 1-2  
8 (15.7%) 
Grade 1-2 
15 (28.3%) 
Grade 1-2 
2 (10%) 
Grade 1-2 
5 (25%) 
 
EBRT – External beam radiotherapy; LDR – Low dose rate; HDR – High dose rate; ICBT – Intracavitary 
brachytherapy;  SCC – Squamous cell carcinoma; FIGO – International federation of gynecology and obstetrics; 
NCI – National cancer institute; CTCAE – Common terminology criteria for adverse events;     ND – Not described.  
Discussion 
In our country most of the cervical cancers are being 
diagnosed in locally advanced or metastatic stages due 
to socioeconomic problems, illiteracy, lack of effective 
implementation of screening programmes, late 
presentation and irregular follow-up.[12,13,14] After 
the NCI statement in 1992 concurrent cisplatin based 
chemoradiation became the standard of choice for 
locally advanced carcinoma cervix. 
CRT in all stages of carcinoma cervix either with 
platinum based or non platinum based drugs improved 
5 years Overall Survival (OS) by 6% and decreased the 
risk of death by 19%. There was no evidence to suggest 
that the benefit of CRT varied according to length of 
cycle, dose intensity of cisplatin but the benefit 
decreases with increasing stage of disease. [15] 
Cisplatin in combination regimens did not gain 
popularity due to greater toxicities. [11, 15,16] 
Weekly cisplatin provides radiosensitisation, by 
inhibiting potentially lethal and sub-lethal damage 
repair and  smaller individual doses of cisplatin may 
lead to less chemotherapy-induced morbidity without 
compromising efficacy. Three  weekly cisplatin is 
popular in head and neck cancers. It was assumed that 
tumor biology of squamous cell carcinoma of the 
cervix and head/neck are similar. High-dose 
chemotherapy may also help in preventing distant 
metastasis by neutralising occult micrometastasis apart 
from radiosensitisation. [16]  
 In the present study, the planned RT treatment was 
completed in 100% of patients in both the arms. 
Scheduled five cycles of concurrent weekly cisplatin 
was completed by only of the 14 patients (70%) in arm 
A and scheduled 2 cycles of concurrent 3 weekly 
cisplatin was completed by 17 (85%) patients in arm B. 
Most common reason for incomplete treatment was 
hematologic toxicity. One patient in arm B had 
treatment interruption. In the study by Ryu et al [9] 
comparing weekly versus triweekly cisplatin based 
CRT; the two regimens were tolerated very well, with 
86.3% and 92.5% completion of scheduled CT cycles 
for the weekly and triweekly arms, respectively. There 
was no statistically significant difference of 
compliance between the two arms (P >0.05). 
According to the study by Chumworathayi et al [11] 
70% had incomplete treatment in the three-weekly 
group and 15% in the weekly cisplatin group.This high 
rate of incomplete treatment was seen for 3rd cycle of 
CT. 
It was observed by patterns of care and survival study 
(POCSS) conducted by ICMR that better survival was 
seen in patients who received optimal RT and 150 mg 
or more of cisplatin and complications increase with 
increasing dose of cisplatin above 150mg. [16] 
Acute toxicities, principally neutropenia and 
gastrointestinal toxicities were more common with 
CRT but were transient. All patients were evaluated 
and graded for different toxicities according to NCI 
CTCAE.  
There was no statistically significant difference 
between hematological toxicities in both arms (anemia, 
leukopenia) and these toxicities were not described in 
Korean study.[9] There was no statistically significant 
difference in neutropenia( 25% VS 10%, P=0.195) in 
between both arms. No grade 3-4 toxicities were 
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observed in this study. In the study by Ryu and 
collegues, grade 1-2 neutropenia was seen in 40% 
patients in both arms and grade 3-4 neutropenia was 
seen in 39% patients in weekly cisplatin arm and 23% 
patients in three weekly cisplatin arm (P = 0.03). [11] 
The lower percentage of neutropenia in this study may 
be due to less cumulative dose of cisplatin given to the 
patients/ less no of cycles of cisplatin.  Lee et al 
compared weekly cisplatin and triweekly combination 
chemotherapy as concurrent adjuvant CRT in post-
operative cases, reported that the weekly cisplatin 
group showed incidence of leucopenia in nearly 85% 
of the cases. Nearly 96% of the patients in triweekly 
group had leucopenia. [10] 
In this study all patients had experienced nausea. 8 
patients of arm A, 6 patients of arm B had grade 1 
vomiting. 5 (25%) patients of arm A and 10 (50%) of 
arm B had grade 2 vomiting (P = 0.208).  Arm B 
patients had more vomiting than arm A patients but 
there was no statistically significant difference. 
According to Ryu et al upper GI toxicity grade 1-2 was 
seen in nearly 80% of the patients in both the weekly 
and three weekly arms. [9] (Table 6).  
In present study, 2 (10%) patients of arm A, 5 (25%) 
patients of arm B had grade 1 nephrotoxicity (P = 
0.212). More patients of arm B experienced 
nephrotoxicity. On comparison to Korean study, 8 
(15.7%) patients of weekly cisplatin arm and 15 
(28.3%) patients of 3 weekly cisplatin arm experienced 
grade 1-2 nephrotoxicity which is comparable to this 
study. 
Many analysis in squamous cell carcinoma of head and 
neck and cervix pointed that accelerated repopulation 
occurs after 4th week of start of RT and this 
repopulation starts early in a fractionated RT. The 
mean duration of treatment should be below 8 weeks as 
suggested by American Brachytherapy Society. [14] 
Prolonged treatment time had an adverse effect on 
outcome because of accelerated repopulation of tumor. 
Any planned or unplanned interruptions or delays 
should be avoided. 
The OTT in this study for both arms ranged from 35-
62 days, with a median of 46 days in arm A and 45 
days in Arm B. It was statistically similar in both 
arms. In the Korean study, treatment delay was 
observed in 2 patients in weekly arm and 1 patient in 
three weekly arm. The treatment delay was defined as 
delay of radiation period (56 days) by 1 week. In this 
study 1 patient in each arm had treatment delay due 
to acute hematological and gastrointestinal toxicity. 
Minor interruptions for 1-2 days resulted from acute 
treatment related toxicities, the RT machine 
breakdown, patient and tumor related factors and the 
gap between EBRT to first HDR ICBT and 
subsequent fractions of ICBT. 
On assessment during 1st follow up, complete response 
was seen in 17 (85% ) patients of arm A , 19 (95%) 
patients of arm B and 3 patients of arm A and 1 patient 
of arm B had partial response  (P = 0.195). This study 
did not show any difference in terms of response 
between the two arms. According to Ryu et al, patients 
in the three weekly cisplatin arm fared better survival 
wise with 88.7% OS at 5 years v/s 66.7% for the 
weekly cisplatin arm. [9] The present study has fewer 
patients and short median follow up of 12 months. 
Longer follow up is required for survival comparison.  
Conclusion 
The above findings from the present study, it can be 
concluded that either concurrent weekly or three 
weekly cisplatin along with radiotherapy can be 
equally effective in the treatment of cervical cancer in 
regard to gastrointestinal and genitourinary toxicities 
and patients compliance towards both chemotherapy 
regimens used concurrently with radiotherapy in 
treatment of locally advanced carcinoma cervix. 
However, further randomised trials with larger sample 
sizes and longer duration of follow up are required to 
reach a consensus. 
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            Figure 1: Study plan 
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